<DOC>
	<DOCNO>NCT00704639</DOCNO>
	<brief_summary>This Phase II study cetuximab , carboplatin radiotherapy ( RT ) patient Locally Advanced Head Neck Carcinomas ( LAHNC ) unfit cisplatin . The aim study show feasibility safety profile combination cetuximab , carboplatin RT treatment patient LAHNC .</brief_summary>
	<brief_title>Chemoradiation Treatment Head Neck Cancer</brief_title>
	<detailed_description>Secondary objective estimate failure free survival ( FFS ) overall survival , evaluate time local regional failure determine site first failure ( characterised local , regional , distant combination ) . Acute late treatment toxicity also evaluate .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Previously untreated SCC oropharynx , larynx hypopharynx . Stage III IV , exclude T1N1 , metastatic disease ( confirm chest CT , abdominal CT ultrasound scan patient abnormal liver function test bone scan FDGPET patient bone pain ) . Histologically cytologically confirm HNSCC Disease must consider potentially curable chemoradiation Patients medically unfit cisplatin chemotherapy due one follow reason : Clinically significant sensorineural hearing impairment ( audiometric abnormality without correspond clinical deafness regard contraindication cisplatin ) Severe tinnitus Renal impairment ( GFR &lt; 60ml/min ) Peripheral neuropathy &gt; grade 2 Inability tolerate intravenous hydration eg due cardiac disease Comorbidities ( base clinical judgement investigator ) associate ECOG PS 2 view investigator would preclude safe administration cisplatin Performance status ECOG 0 , 1 2 . Adequate haematological , renal hepatic function define : Absolute neutrophil count ( ANC , segment cell ( segs ) + band ) &gt; = 1.5 x 109/L Platelet count &gt; = 100 x 109/L Total bilirubin &lt; = 1.5 x upper normal limit Alanine aminotransferase &lt; = 2.5 x upper normal limit Calculated creatinine clearance &gt; 40ml/min ( CockcroftGault formula ) . If calculate creatinine clearance &lt; 50 ml/min , glomerular filtration rate measure DTPA EDTA scan . If &lt; 40 ml/min eligible . Age &gt; 18 year Signed write consent Suitable followup 4 year view investigator Distant metastases , i.e. , metastatic disease clavicle . Patients lung nodule &gt; 10mm exclude unless nonmalignancy aetiology establish . Patients lesion 510mm include FDGPET scan negative investigator considers clinical ground metastasis unlikely . Patients lesion &lt; 5mm include investigator considers clinical ground metastases unlikely . Patients multiple lung nodule include unless strong case represent metastasis , e.g. , stable image 12 month , nonmalignant aetiology apparent . The level clinical suspicion may influence clinical stage , e.g. , N3 disease , low neck node . In general doubt patient exclude . Previous radical RT head &amp; neck region , exclude superficial RT nonmelanomatous skin cancer . Patients prior cancer , except : diagnosed &gt; 5 year ago evidence disease recurrence clinical expectation recurrence le 5 % ; successfully treat nonmelanoma skin cancer ; carcinoma situ cervix . Significant intercurrent illness interfere chemotherapy radiation therapy HIV infection , cardiac failure , pulmonary compromise , active infection Any history myocardial infarction , ventricular arrhythmia , unstable angina within last 6 month Pregnant lactating woman . Weight loss great 20 % usual body weight 3 month precede trial entry High risk poor compliance therapy follow assess investigator Prior radiation great 30 % bone marrow Prior systemic chemotherapy cancer Refusal male female patient , use appropriate contraception study 3 month afterwards Any condition circumstance might prevent patient able give valid inform consent , complete participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Head Neck</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>